Startups, Biotech, By Meghana Keshavan http://medcitynews.com.
The startup’s developing gene therapies for rare neurologic diseases, which include Giant axonal neuropathy (GAN), Canavan disease, Friedreich’s ataxia as well as Duchenne muscular dystrophy. Bamboo’s most advanced program is its therapeutic for GAN, which is currently in Phase 1/2 trials. CBS News ran a piece on Bamboo’s approach to GAN in October.
Saturday, February 20, 2016
Subscribe to:
Posts (Atom)
